Please try another search
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Joshua N. Silverman | 51 | 2016 | Independent Chairman of the Board |
William S. Singer | 80 | 2013 | Independent Vice-Chairman of the Board |
Daniel L. Alkon | 79 | 2020 | President, Chief Scientific Officer & Director |
Paul Coleman | - | - | Member of Scientific Advisory Board |
Alan J. Tuchman | 74 | 2020 | CEO & Director |
Jonathan L. Schechter | 47 | 2018 | Independent Director |
Lee Jen Wei | - | - | Member of Scientific Advisory Board |
Daniel F. Hanley | 72 | - | Member of Scientific Advisory Board |
Marwan Noel Sabbagh | - | - | Member of Scientific Advisory Board |
Martin Rhys Farlow | - | - | Member of Scientific Advisory Board |
George Perry | 68 | 2017 | Chairman of the Scientific Advisory Board |
Bruce T. Bernstein | 58 | 2016 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review